Clinical Trials Browser

Withdrawn × Disease Progression × Clear all

NCT04029038 2023-08-21

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Disease Progression

NCT05116618 2022-09-21

Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

Carcinoma, Non-Small-Cell Lung, Disease Progression

NCT04044378 2020-05-19

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Phase 1/2 Withdrawn

Neoplasms, Disease Progression

NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Phase 2 Withdrawn

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

NCT01210131 2013-08-27

HX4 in SCLC

Phase NA Withdrawn

Disease Progression, Small Cell Lung Carcinoma

NCT01340729 2013-04-05

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

Phase 1/2 Withdrawn

Melanoma, Recurrence, Disease Progression

NCT00172367 2008-09-26

Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

Phase 2 Withdrawn

Carcinoma, Transitional Cell, Uremia, Disease Progression